PureTech Health plc

PTCHF
About the company

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody.

Country: United StatesPrice: $1.65Market Cap: $402.9M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

7 / 9

NEUTRAL / FAIL

Median fair value

$2.54

+53.5% vs price

Models with upside

4 / 17

Positive margin of safety

Strongest signal

PTCHF undervalued: all 4 models price fair value above $1.65 (median $2.54)

Key risk

No clean pass — all 8 investors flag at least one growth criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2923 (Top 94.4%)NEUTRALNEUTRALNEUTRALNEUTRALFAILFAILFAILNEUTRALFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety+42.1%+41.3%N/AN/AN/AN/AN/A+26.8%N/A+12.4%N/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Where It Passes

  • Valuation models100% pass✓ 4▾

    PTCHF undervalued: all 4 models price fair value above $1.65 (median $2.54)

    Graham fair value$2.86
    ✓Graham+42.1% margin vs $1.65
    Buffett fair value$2.82
    ✓Buffett+41.3% margin vs $1.65
    Pabrai fair value$2.26
    ✓Pabrai+26.8% margin vs $1.65
    Marks fair value$1.89
    ✓Marks+12.4% margin vs $1.65
  • Debt & Leverage67% pass✓ 11✗ 4▾

    8 of 12 pass — Graham, Buffett, Lynch +1 more object

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.04, IC: -78.6x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.04
    ✓Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities9.33
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.04
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.04
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-78.6x, D/EBITDA=N/A
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.04
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0440; #972/4210 (top 23.1%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Growth0% pass✓ 2✗ 11▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)-110.9%
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)P/E 7.9x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR-32.0%
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthN/A (no inventory)
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$-0.16 (2018) -> $0.21 (2024)
    ✓DremanPositive over recent years
    EPS CAGR-32.0% CAGR over 5 years
    ✗Dreman> 5% annualized
    Positive Net Income Frequency3/7 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-10.2%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency2/5 years with positive EPS growth
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR-32.0% CAGR over 5 years
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendrevenue flat/down, operating margin -1266.5% -> -2818.9%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR-13.2%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR-32.0% over 5 years
    ✗Neff7%-20% annualized
  • Verdicts0% pass✗ 10▾

    Split decision: 9 FAIL · 7 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (2/7)✗GreenblattRank #2923•PiotroskiNEUTRAL (F-Score 6)•DremanNEUTRAL (7/11)•MungerNEUTRAL (3/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✗AckmanFAIL (2/9)•TempletonNEUTRAL (5/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
  • Profitability19% pass✓ 9✗ 26▾

    13 of 16 flag PTCHF's profitability — Graham, Buffett, Lynch +10 more

    Positive EPS (10 years)3/8 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)-110.9%
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)3/8 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-4.0%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-2818.9% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$57.1M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)4.43
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)P/E 7.9x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR-32.0%
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE12.9%
    ✗Lynch> 15%
    EBIT / Enterprise Value-96.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-96.9%, ROC=-190.9%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets8.88%
    ✓PiotroskiROA > 0
    ROA Change YoY-9.47% -> 8.88% (delta: +18.35%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-22.30%, ROA=8.88%
    ✗PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue492.4%
    ✓Dreman>= 8%
    Net Income / Shareholders' Equity12.9%
    ✓Dreman> 12%
    Margin of SafetyP/E=7.9x, P/B=1.0x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-3.5% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency3/7 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-2818.9%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity12.9%
    ✗Ackman>= 15%
    5-Year EPS CAGR-32.0% CAGR over 5 years
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-1266.5% (2022) -> -2818.9% (2024)
    ✗TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendrevenue flat/down, operating margin -1266.5% -> -2818.9%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+13.28%; #434/6340 (top 6.8%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity+12.90%; #1397/5226 (top 26.7%)
    ✓AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0670; #2955/5884 (top 50.2%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR-32.0% over 5 years
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years3/7 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Cash Flow20% pass✓ 2✗ 10▾

    8 of 10 flag PTCHF's cash flow — Lynch, Piotroski, Dreman +5 more

    Free Cash Flow Proxy$57.1M
    ✓BuffettPositive and growing
    FCF Positive and Growing$-134.4M
    ✗LynchPositive and growing
    Operating Cash Flow$-134.4M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-22.30%, ROA=8.88%
    ✗PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldP/E=7.9x, FCF Yield=-33.4%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/7 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-33.9%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency0/7 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-134.4M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-33.36%; #3704/4519 (top 82.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Valuation31% pass✓ 14✗ 14▾

    9 of 13 flag PTCHF's valuation — Graham, Lynch, Greenblatt +6 more

    Price / Book Value per Share1.0x
    ✓Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio1.0x
    ✓Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)P/E 7.9x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-96.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-96.9%, ROC=-190.9%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS7.9x
    ✓Dreman< 12x✓Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Valuation ReasonablenessP/E=7.9x, OE Yield=14.4%
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=7.9x, FCF Yield=-33.4%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=7.9x, P/B=1.0x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low107% of trailing low ($1.54)
    ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+13.28%; #434/6340 (top 6.8%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+1.0294; #1436/6449 (top 22.3%)
    ✓AsnessTop 30% of eligible cross-section
    Price / Diluted EPS7.9x
    ✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share0.96x
    ✓SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-26.0%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.0120; #4829/5247 (top 92.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-33.36%; #3704/4519 (top 82.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-1.90%; #2916/6202 (top 47.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Efficiency38% pass✓ 4✗ 7▾

    5 of 8 flag PTCHF's efficiency — Buffett, Greenblatt, Munger +2 more

    Current Ratio9.33
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-53.6%
    ✗Buffett> 10%
    ROIC - WACC-63.6%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-190.9%
    ✗Greenblatt> 25%
    Current Ratio Change YoY6.76 -> 9.33
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.00x -> 0.01x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities9.33
    ✓Dreman> 1.5
    Return on Invested Capital-24.8%
    ✗Munger> 15%
    ROIC (high and growing)FY2022: ROIC=-28.0%; FY2023: ROIC=-24.9%; FY2024: ROIC=-24.8%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC-24.8% (RR=100% x ROIC=-24.8%)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest -24.8%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Small Cap($402.9M)
Revenue: $4.8M+45.0% YoY
Net Income: $53.5M+181.4% YoY

Financial Snapshot

Operating Margin-2818.9%
Return on Equity12.9%
Debt / Equity0.04
Current Ratio9.33
EPS (Diluted)$0.21
Buybacks (1y)$4.8M
Buybacks (2y)$24.4M
Shares Retired11.9% / 14.1% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2024

Retired 11.9% of shares last year, 14.1% over two.

Buybacks
$4.8M
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

MetricFY 2024
Sources
  • 20-F · 2025-04-30
FY 2023
Sources
  • 20-F · 2024-04-25
FY 2022
Sources
  • 20-F · 2023-04-28
FY 2021
Sources
  • 20-F · 2022-04-26
FY 2020
Sources
  • 20-F · 2021-04-15
Market Cap$402.9Mcurrent$660.6Mest.$874.7Mest.$1.0Best.$1.5Best.
Revenue$4.8M↑45%$3.3M↓79%$15.6M↓10%$17.4M↑48%$11.8M
Operating Income-$136.1M↑7%-$146.2M↑26%-$197.8M↓32%-$150.3M↓26%-$119.5M
Net Income$53.5M↑181%-$65.7M↓30%-$50.4M↑17%-$60.6M↓1112%$6.0M
EPS (Diluted)$0.21↑187%$-0.24↓33%$-0.18↑14%$-0.21↓1150%$0.02
Gross Margin—————
Operating Margin-2818.9%↑36%-4390.4%↓247%-1266.5%↓47%-864.3%↑15%-1015.7%
ROE12.9%↑191%-14.2%↓52%-9.3%↑9%-10.2%↓1242%0.9%
Total Debt$18.3M$0↓100%$15.4M↑2%$15.1M↑2%$14.8M
Shareholders' Equity$414.7M↓11%$464.1M↓14%$542.2M↓9%$593.5M↓11%$669.7M
Current Ratio9.33↑38%6.76↑70%3.99↑80%2.22↓3%2.29
Debt / Equity0.040.00↓100%0.03↑12%0.03↑15%0.02
Operating Cash Flow-$134.4M↓27%-$105.9M↑41%-$178.8M↓13%-$158.3M↓20%-$131.8M
Free Cash Flow-$134.4M↓27%-$106.0M↑41%-$181.0M↓10%-$163.8M↓20%-$137.0M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

PTCHF vs Peers — Financial Grading

Revenue$4.8MBottom 25%
Net Income$53.5MMedian
ROE12.9%Top 25%
D/E0.04Top 25%
Op. Margin-2818.9%Bottom 25%
Curr. Ratio9.33Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11